Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control.
Brief Summary: Using an established model of human typhoid infection, whereby healthy adults are deliberately infected with typhoid-causing bacteria, the investigators will determine how effective a new oral typhoid vaccine (M01ZH09) is in preventing infection. A previously licensed oral typhoid vaccine (Ty21a) will be used to make sure the challenge model used works properly.


Options:
A: Arm Label: Vi-CRM, Adults; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: Vi-PS, Adults; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi Polysaccharide (PS) vaccine | Arm Label: Vi-CRM, Children; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: Vi-PS, Children; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi Polysaccharide (PS) vaccine, Biological: Pneumococcal conjugate vaccine | Arm Label: Vi-CRM, Older infants; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: PNC13, Older infants; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pneumococcal conjugate vaccine | Arm Label: Vi-CRM, Infants; Type: EXPERIMENTAL; Interventions: Biological: Vi-CRM197 vaccine | Arm Label: PNC13, Infants; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pneumococcal conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Vi-CRM197 vaccine; Assigned to Arm(s): Vi-CRM, Adults, Vi-CRM, Children, Vi-CRM, Infants, Vi-CRM, Older infants | Intervention Type: BIOLOGICAL; Name: Vi Polysaccharide (PS) vaccine; Assigned to Arm(s): Vi-PS, Adults, Vi-PS, Children | Intervention Type: BIOLOGICAL; Name: Pneumococcal conjugate vaccine; Assigned to Arm(s): PNC13, Infants, PNC13, Older infants, Vi-PS, Children
B: Arm Label: M01ZH09 vaccine; Type: EXPERIMENTAL; Interventions: Biological: M10ZH09 vaccine | Arm Label: Vaccine placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vaccine placebo (excipients only) | Arm Label: Ty21a vaccine; Type: OTHER; Interventions: Biological: Ty21a | Intervention Type: BIOLOGICAL; Name: Vaccine placebo (excipients only); Assigned to Arm(s): Vaccine placebo | Intervention Type: BIOLOGICAL; Name: Ty21a; Assigned to Arm(s): Ty21a vaccine | Intervention Type: BIOLOGICAL; Name: M10ZH09 vaccine; Assigned to Arm(s): M01ZH09 vaccine
C: Arm Label: NVGH Vi-CRM197 conjugate vaccine 12.5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 12.5 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 5.0 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 1.25 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 1.25 mcg | Arm Label: Typherix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 12.5 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 12.5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 5.0 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 1.25 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 1.25 mcg | Intervention Type: BIOLOGICAL; Name: Vi-polysaccharide vaccine; Assigned to Arm(s): Typherix
D: Arm Label: Vi-TCV; Type: EXPERIMENTAL; Interventions: Biological: Vi-TCV | Arm Label: Vi-PS Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-PS Vaccine | Arm Label: Control (Men ACWY); Type: OTHER; Interventions: Biological: Control (Men ACWY) | Intervention Type: BIOLOGICAL; Name: Vi-TCV; Assigned to Arm(s): Vi-TCV | Intervention Type: BIOLOGICAL; Name: Vi-PS Vaccine; Assigned to Arm(s): Vi-PS Vaccine | Intervention Type: BIOLOGICAL; Name: Control (Men ACWY); Assigned to Arm(s): Control (Men ACWY)

Answer: B